Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap

[cafead]

via Some four years after it reported its first batch of pivotal trial data, Tetraphase finally secured FDA approval for its lead antibiotic, eravacycline, for complicated intra-abdominal infections in 2018. But like many of its peers, merely securing approval was only the first hurdle.

article source

 

[anonymous]

Still selling Xerava... have not "bit the dust yet"...